Qiagen N.V. (QGEN) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $37.28 (+0.73%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 6, 2026 | Cathy Ramsey Schulte | Robert W. Baird | $53.00 | +42.2% |
| Jan 22, 2026 | Jan Koch | Deutsche Bank | $54.00 | +44.8% |
| Oct 2, 2025 | Catherine Ramsey Schulte | Barclays | $55.79 | +49.6% |
| Oct 17, 2024 | Shubhangi Gupt | HSBC | $51.58 | +38.4% |
| Jun 27, 2024 | Doug Schenkel | Wolfe Research | $52.63 | +41.2% |
| Jun 18, 2024 | John Sourbeer | UBS | $48.42 | +29.9% |
| Nov 4, 2021 | Daniel Brennan | Cowen & Co. | $61.05 | +63.8% |
| Jul 15, 2021 | Derik De Bruin | Bank of America Securities | $54.74 | +46.8% |
| Jul 14, 2021 | Patrick B Donnelly | Citigroup | $61.05 | +63.8% |
| Jul 13, 2021 | Ulrich Huwald | Warburg Research | $52.89 | +41.9% |
Top Analysts Covering QGEN
QGEN vs Sector & Market
| Metric | QGEN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.67 | 2.24 | 2.40 |
| Analyst Count | 12 | 8 | 19 |
| Target Upside | +21.7% | +11475.0% | +17.1% |
| P/E Ratio | 19.72 | 3.89 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.20B | $2.21B | $2.24B | 12 |
| 2027-03-31 | $527M | $531M | $536M | 4 |
| 2027-06-30 | $579M | $585M | $590M | 3 |
| 2027-09-30 | $597M | $602M | $607M | 3 |
| 2027-12-31 | $610M | $615M | $620M | 3 |
| 2028-03-31 | $547M | $552M | $556M | 2 |
| 2028-06-30 | $603M | $609M | $614M | 5 |
| 2028-09-30 | $624M | $630M | $636M | 4 |
| 2028-12-31 | $639M | $645M | $650M | 4 |
| 2029-12-31 | $2.62B | $2.63B | $2.66B | 5 |
| 2030-12-31 | $2.75B | $2.77B | $2.80B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.45 | $2.51 | $2.77 | 9 |
| 2027-03-31 | $0.60 | $0.61 | $0.61 | 3 |
| 2027-06-30 | $0.67 | $0.68 | $0.69 | 2 |
| 2027-09-30 | $0.71 | $0.72 | $0.73 | 2 |
| 2027-12-31 | $0.73 | $0.74 | $0.75 | 2 |
| 2028-03-31 | $0.66 | $0.67 | $0.67 | 3 |
| 2028-06-30 | $0.73 | $0.74 | $0.75 | 6 |
| 2028-09-30 | $0.76 | $0.77 | $0.78 | 5 |
| 2028-12-31 | $0.78 | $0.79 | $0.79 | 5 |
| 2029-12-31 | $3.25 | $3.27 | $3.32 | 2 |
| 2030-12-31 | $3.51 | $3.54 | $3.59 | 2 |
Frequently Asked Questions
What is the analyst consensus for QGEN?
The consensus among 12 analysts covering Qiagen N.V. (QGEN) is Hold with an average price target of $54.33.
What is the highest price target for QGEN?
The highest price target for QGEN is $61.05, set by Daniel Brennan at Cowen & Co. on 2021-11-04.
What is the lowest price target for QGEN?
The lowest price target for QGEN is $48.42, set by John Sourbeer at UBS on 2024-06-18.
How many analysts cover QGEN?
12 analysts have issued ratings for Qiagen N.V. in the past 12 months.
Is QGEN a buy or sell right now?
Based on 12 analyst ratings, QGEN has a consensus rating of Hold (2.67/5) with a +21.7% upside to the consensus target of $54.33.
What are the earnings estimates for QGEN?
Analysts estimate QGEN will report EPS of $2.51 for the period ending 2026-12-31, with revenue estimated at $2.21B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.